ImmuPharma plc (AIM: IMM)
London
· Delayed Price · Currency is GBP · Price in GBX
2.822
-0.258 (-8.39%)
Jan 22, 2025, 12:10 PM GMT+1
ImmuPharma Revenue
ImmuPharma had revenue of -69.96K GBP in the twelve months ending June 30, 2024, down -200.00% year-over-year.
Revenue (ttm)
-69.96K
Revenue Growth
-200.00%
P/S Ratio
n/a
Revenue / Employee
-13.99K
Employees
5
Market Cap
12.83M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
ImmuPharma News
- 12 days ago - AIM Market Roundup: Immupharma, Poolbeg, Xeros - The Armchair Trader
- 4 months ago - Three Quick Facts: Norman Broadbent, Computacenter, Immupharma - The Armchair Trader